Cephapirin sodium, a cephalosporin for parenteral use, was evaluated in vitro and in 27 patients. Cephapirin had activity equivalent to cephalothin against 25 strains each of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus aureus; 10 strains each of Diplococcus pneumoniae, Pseudomonas species, and Enterobacter species; and 8 strains of Proteus species other than P. mirabilis. All strains of S. aureus and D. pneumoniae and most strains of E. coli, K. pneumoniae, and Proteus species were inhibited by concentrations of cephapirin achieved in the serum. Of 27 patients (20 with pneumonia, 2 with S. aureus empyema, and 5 with miscellaneous infections), 25 responded to cephapirin therapy. The only major toxicity thought to be drug-related occurred in a patient who developed reversible bone marrow depression with leukopenia, neutropenia, and anemia. Although cephapirin was painful on intramuscular injection, phlebitis and pain were absent in patients treated intravenously. In a controlled comparison of intravenously administered cephalothin and cephapirin in four additional patients, the latter caused much less pain than the former and caused no phlebitis.
Cephapirin sodium, a new cephalosporin C antibiotic for parenteral use, is bactericidal against strains of gram-positive and gram-negative bacteria including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (1). Although cephapirin sodium has a spectrum similar to that of cephalothin sodium, studies in human volunteers have indicated that it is less painful and better tolerated than cephalothin when given by intramuscular or intravenous injection (1).
The present investigation was undertaken to determine the in vitro antibacterial activity of cephapirin sodium and to evaluate it in the treatment of infections in humans.
MATERIALS AND METHODS
In vitro susceptibility tests. The following strains of bacteria were isolated from patients: 25 strains each of Escherichia coli, Klebsiella pnieumoniae, Proteus mirabilis, and Staphylococcus aureus; 10 strains each of Diplococcus pneumoniae (Streptococcus pneumoniae), Pseudomonas species, and Eniterobacter species; and 8 strains of Proteus species other than P. mirabilis.
The susceptibility of the organisms to cephapirin sodium and cephalothin sodium was determined by a dilution method in Trypticase Soy Broth at pH 7.3. The antibiotics were diluted in twofold steps in tubes containing 0.5 ml of broth. The bacterial inoculum for each tube was 0.5 ml of a 1O-4 dilution of an 18-hr culture of each strain in Trypticase Soy Broth. Studies on D. pneumoniae were performed in Trypticase Soy Broth with 2% sheep blood. The bacteriostatic end point was considered to be the lowest concentration of antibiotic that prevented turbidity after 24 hr of incubation at 37 C. At 24 hr, 0.001 ml was removed from each tube without visible growth by use of a sterile platinum loop and streaked on plates of Trypticase Soy Agar containing blood. After incubation at 37 C for 24 hr, the plates were examined, and the lowest concentration of antibiotic that resulted in no growth was taken as the minimal bactericidal end point.
Determination of drug concentrations in serum and urine. Serum and urine concentrations of cephapirin sodium were determined in patients receiving parenteral cephapirin during the third to fifth days of therapy. Blood was obtained 1 hr after administration of a dose of cephapirin sodium. Urine specimens were obtained by having the patient void before receiving a dose of cephapirin and collecting urine voided during and at the end of the following 6-hr interval. Serum was separated and stored at -20 C until the time of assay. Urine was stored at -20 C and filtered through a 0.45-Am filter before assay.
The concentrations of cephapirin in serum and urine were determined by the agar-diflusion method described by Wick with the use of paper discs (4, 5) . A 24-hr culture of Sarcinia lutea (ATCC 9341) was washed from the surface of a Trypticase Soy Agar slant with nutrient broth adjrsted to pH 6.6. This suspension was adjusted to 80% of light transmittance at 660 nm in a spectrophotometer by adding nutrient broth.
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A volume of 1.25 ml of the suspension was then mixed with 100 ml of melted nutrient agar which had been adjusted to pH 6.6. Pour plates were made with 10 ml for each plate and were allowed to harden. Sterile paper discs were submerged in known concentrations of cephapirin sodium freshly prepared in pooled human serum. The discs were also submerged in patients' sera. The discs were placed on the pour plates and incubated at 26 C for 24 hr. The temperature of 26 C was used because zones of inhibition are clearer at 26 C than at 37 C. Each known and unknown serum was plated in quadruplicate. A known serum was plated on each pour plate to measure uniformity of the plates. Zones of inhibition were determined with an antibiotic zone reader, and a standard curve was constructed from the known concentrations of cephapirin sodium. Concentrations of cephapirin sodium in the patients' sera were determined from this curve. Sera containing more than 12.5 ,Ag/ml were diluted 1:3 in pooled human sera for determination of the concentrations.
Urine concentrations of cephapirin sodium were determined in the same manner with two exceptions: (i) The urine specimens were diluted 1:100 and 1:1,000 in nutrient broth at pH 6.6 before the determinations were performed, and (ii) the standard curve was constructed from known concentrations of antibiotic in nutrient broth. mirabilis were inhibited by 6.3,ug of cephapirin sodium/ml, and most strains of E. coli were inhibited by 12.5,ug/ml. Most strains of Enterobacter species and all strains of Pseudomonas species were resistant to 50 Mg of cephapirin/ml.
Cephapirin sodium concentrations in serum and urine. As shown in Table 1 , 1 hr after rapid intravenous administration of 1 g of cephapirin sodium, concentrations in the serum ranged from 5.7 to 17.0 ,g/ml (mean, 11.3,ug/ml). One hour after intramuscular injection of 1 g, serum concentrations ranged from 7.2 to 25.1 jig/ml (mean, 15.1 ,ug,/ml).
During the 6 hr after administration of 1 g by the intravenous or intramuscular route, urine concentrations of cephapirin ranged from 300 to 2,500 Mg/ml. During this 6-hr collection, 30 to 89-, of injected cephapirin activity was recovered in the urine (excluding one patient in whom the urine collection was incomplete).
Clinical studies with cephapirin sodium. The clinical data are summarized in One patient (no. 11), who received cephapirin for 6 days, developed anemia, leukopenia, and neutropenia. The white cell count decreased from 4,600/mm3 of blood with 86% neutrophils to 3,000/mm3 with only 15% neutrophils over a period of 7 days from the start of cephapirin. The hemoglobin fell from 14 to 11 g/100 ml over a period of 18 days from the start of cephapirin therapy. Bone marrow examination showed maturation arrest of the white cell series at the stage of metamyelocytes 18 days after onset of therapy with cephapirin. The white blood cell count and differential returned to normal by 6 days and the hemoglobin by 19 days after treatment was stopped.
All other laboratory tests on the 27 patients which were previously normal were not altered by therapy.
DISCUSSION
Cephapirin sodium and cephalothin sodium were equally active against strains of E. coli, K. pneumoniae, P. mirabilis, S. aureus, D. pneumoniae, and Proteus species other than P. mirabilis. All strains of Pseudomonas species and most strains of Enterobacter species were resistant to both drugs. These results are similar to those of The present investigation has demonstrated that cephapirin reaches effective concentrations in the blood and urine after parenteral administration. Mean serum concentrations 1 hr after administration of 1 g of cephapirin were 11.3 and 15.1 Ag/ml for the intramuscular and intravenous injections, respectively. Even though 1 hr is past the time at which a peak concentration is expected, these concentrations were high enough to inhibit all strains of D. pneumoniae and S. aureus and most strains of K. pneumoniae, P. mirabilis, E. coli, and Proteus species other than P. mirabilis. More than 85 % of strains of E. coli, P. mirabilis, and K. pneumoniae were inhibited by concentrations of cephapirin achieved in the urine.
In this study, 25 of the 27 patients responded clinically and bacteriologically to cephapirin therapy. The one patient who died had end-stage renal failure and pneumonia caused by a K. pneumoniae strain resistant to cephapirin. The other patient who did not respond promptly had pneumonia caused by anaerobic bacteria following aspiration.
The eosinophilia observed in three patients was probably related to administration of cephapirin. The elevations in SGOT were thought to be due to intramuscular injections in at least two of three patients. The cause of the decrease in hematocrit and elevation in BUN in one patient was difficult to evaluate.
The major side effect from cephapirin was the development of bone marrow depression with leukopenia, neutropenia, and anemia in one patient. This was thought to be related to cephapirin. Neutropenia apparently caused by cephalosporins has been reported in rare instances previously (2) . Although reversible, this serious side effect is disturbing and should be watched for with use of cephapirin and other cephalosporins.
Cephapirin and cephalothin seem to be equivalent drugs with respect to antibacterial activity. The major advantage of cephapirin over cephalothin would seem to be that less pain and phlebitis result from intravenous administration of cephapirin.
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